Arcutis Biotherapeutics (ARQT) insider plans Rule 144 sale after prior stock disposal

Rhea-AI Filing Summary

Arcutis Biotherapeutics insider Todd F. Watanabe filed to sell common stock under Rule 144. The planned sale covers 4,375 shares of common stock that became eligible for sale through restricted stock vesting on August 1, 2026. The shares are listed on NASDAQ and are held through a Merrill Lynch account in Columbus, Ohio.

Within the preceding three months, Watanabe previously sold 3,172 common shares on May 4, 2026 for total proceeds of $74,892.82. This filing provides advance notice of the planned disposition of additional shares.

Key Figures

Planned shares to be sold: 4,375 shares Prior shares sold: 3,172 shares Proceeds from prior sale: $74,892.82 +2 more

5 metrics

Planned shares to be sold 4,375 shares Common stock planned for sale under Rule 144

Prior shares sold 3,172 shares Common stock sold during the past 3 months

Proceeds from prior sale $74,892.82 Total consideration for 3,172 shares sold on May 4, 2026

Vesting date 08/01/2026 Restricted stock vesting date for the 4,375 shares

Exchange NASDAQ Listing venue for Arcutis Biotherapeutics common stock

Key Terms

Rule 144, Restricted Stock Vesting, securities to be sold

3 terms

Rule 144 regulatory

"insider Todd F. Watanabe filed to sell common stock under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 08/01/2026 | Restricted Stock Vesting | Arcutis Biotherapeutics"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

securities to be sold regulatory

"144: Securities To Be Sold Common | 08/01/2026 | Restricted Stock Vesting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 05:07 PM Accepted by SEC EDGAR 08/03/2026 - 05:07 PM Learn about SEC filing dates

FAQ

What stock sale is Todd F. Watanabe planning for Arcutis Biotherapeutics (ARQT)?

Todd F. Watanabe plans to sell 4,375 shares of Arcutis Biotherapeutics common stock under Rule 144. The shares relate to restricted stock vesting on August 1, 2026 and are listed for trading on NASDAQ.

How many Arcutis Biotherapeutics (ARQT) shares did Todd F. Watanabe sell recently?

Over the past three months, Todd F. Watanabe sold 3,172 shares of Arcutis Biotherapeutics common stock. The sale occurred on May 4, 2026 and generated total proceeds of $74,892.82.

What is the origin of the Arcutis Biotherapeutics (ARQT) shares being sold by Todd F. Watanabe?

The 4,375 shares Todd F. Watanabe plans to sell are tied to restricted stock vesting. The vesting date listed is August 1, 2026, indicating the shares became eligible for sale at that time.

On which exchange are Todd F. Watanabe’s Arcutis Biotherapeutics (ARQT) shares listed?

The common shares referenced in Todd F. Watanabe’s Rule 144 filing are listed on NASDAQ. The shares are held in a brokerage account at Merrill Lynch in Columbus, Ohio, according to the filing details.

What information does this Rule 144 notice for Arcutis Biotherapeutics (ARQT) provide investors?

The notice discloses a planned sale of 4,375 vested restricted shares and a prior sale of 3,172 shares for $74,892.82. It informs investors of upcoming and recent insider stock dispositions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	4375	114261	125083374	08/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			4375	08/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Todd F Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	05/04/2026	3172	74892.82

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)